CN113952429A - 一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 - Google Patents
一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113952429A CN113952429A CN202111452072.6A CN202111452072A CN113952429A CN 113952429 A CN113952429 A CN 113952429A CN 202111452072 A CN202111452072 A CN 202111452072A CN 113952429 A CN113952429 A CN 113952429A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- lung injury
- decoction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 206010069351 acute lung injury Diseases 0.000 title claims abstract description 25
- 239000002158 endotoxin Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000001404 mediated effect Effects 0.000 title claims abstract description 16
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 11
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 11
- 241000490229 Eucephalus Species 0.000 claims abstract description 11
- 241001522129 Pinellia Species 0.000 claims abstract description 11
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 235000020224 almond Nutrition 0.000 claims abstract description 11
- 241001633574 Adenophora stricta Species 0.000 claims abstract description 9
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 5
- 241000675108 Citrus tangerina Species 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 208000004852 Lung Injury Diseases 0.000 claims description 8
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 8
- 231100000515 lung injury Toxicity 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 7
- 241000605445 Anemarrhena asphodeloides Species 0.000 claims description 6
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 6
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 6
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 6
- 240000007078 Peucedanum palustre Species 0.000 claims description 6
- 235000008040 Peucedanum palustre Nutrition 0.000 claims description 6
- 235000006751 Platycodon Nutrition 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 6
- 229930189914 platycodon Natural products 0.000 claims description 6
- 241000935235 Fritillaria meleagris Species 0.000 claims description 5
- 241001673966 Magnolia officinalis Species 0.000 claims description 5
- 241001671204 Stemona Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004072 lung Anatomy 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 5
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 5
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 210000002919 epithelial cell Anatomy 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 14
- 241000219112 Cucumis Species 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000000495 immunoinflammatory effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241001412627 Adenophora liliifolia Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010029538 Non-cardiogenic pulmonary oedema Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001626 effect on respiratory system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法,属于中药配方领域。该中药组合物,包括以下重量份的组分:麦冬4‑15份、双皮3‑15份、沙参3‑15份、炒杏仁4‑15份、百部3‑15份、前胡5‑15份、紫苑4‑15份、半夏4‑12份、青皮5‑15份、桔梗4‑15份、茯苓3‑12份、川贝母3‑15份、瓜蔓4‑15份、厚朴5‑15份、黄芩3‑12份、知母4‑12份、桔红5‑15份。本发明的中药组合物能够有效抑制肺组织炎症的发生、抑制炎性因子IL‑1β、IL‑6和TNF‑α的分泌,减轻肺上皮细胞炎性损伤,对急性肺损伤具有很好的治疗效果。
Description
技术领域
本发明涉及中药配方领域,特别是涉及一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法。
背景技术
急性肺损伤(Acute lung injury,ALI)/急性呼吸窘迫综合征(Acuterespiratory distress syndrome,ARDS)是继发于肺内或全身的炎症反应过程,是由各种直接或间接因素导致肺泡上皮细胞及毛细血管内皮细胞损伤,造成弥漫性肺间质和肺泡水肿,进而导致急性低氧性呼吸功能不全;急性肺损伤由肺泡损伤导致并形成炎症性非心源性的肺水肿,表现为肺泡间壁变厚、炎症细胞浸润、凝血失控、低氧血症等。目前对于ALI的防治主要以西医治疗为主,其虽能减轻临床症状,却无法明显控制病情进展,具有一定局限性,另外,西药还存在副作用较大的缺点,因此寻找其他防治ALI的药物仍然是当今人们所关注的热点课题。传统中药及天然药物以其疗效高、副作用小的特点一直是创新药物发现的源泉,因此,提出一种能够有效防治急性肺损伤的中药组合物是非常有必要的。
发明内容
本发明的目的是提供一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法,以解决上述现有技术存在的问题,该中药组合物配伍科学合理,治疗效果优异,提高了患者的生活质量,也为治疗急性肺损伤提供了一条新的途径。
为实现上述目的,本发明提供了如下方案:
本发明提供一种防治内毒素介导的急性肺损伤的中药组合物,包括以下重量份的组分:麦冬4-15份、双皮3-15份、沙参3-15份、炒杏仁4-15份、百部3-15份、前胡5-15份、紫苑4-15份、半夏4-12份、青皮5-15份、桔梗4-15份、茯苓3-12份、川贝母3-15份、瓜蔓4-15份、厚朴5-15份、黄芩3-12份、知母4-12份、桔红5-15份。
进一步地,包括以下重量份的组分:麦冬10份、双皮8份、沙参8份、炒杏仁10份、百部8份、前胡12份、紫苑10份、半夏10份、青皮12份、桔梗10份、茯苓8份、川贝母8份、瓜蔓10份、厚朴12份、黄芩8份、知母10份、桔红12份。
本发明还提供一种所述的中药组合物的制备方法,包括以下步骤:
S1.按照配比将原料混合后,加水浸泡;
S2.将浸泡后的原料进行第一次煎煮,收集第一煎药液;
S3.再向原料中加入与第一煎相同的水量,采用与第一煎相同的条件进行第二次煎煮,收集第二煎药液;
S4.合并第一煎药液和第二煎药液即可。
进一步地,步骤S1中所述加水用量为过药面2-3cm,所述浸泡水温为35℃-55℃,所述浸泡时间为40-60min。
进一步地,步骤S2中所述煎煮为煮沸后文火煎煮20-30min。
本发明还提供一种防治肺损伤的中药制剂,包括治疗有效量的所述的中药组合物。
进一步地,所述中药制剂为口服制剂。
本发明还提供一种所述的中药组合物在制备防治肺损伤药物中的应用。
进一步地,所述肺损伤包括内毒素介导的急性肺损伤和/或脂多糖引起的肺损伤。
本发明公开了以下技术效果:
本发明的中药组合物能够有效抑制肺组织炎症的发生、抑制炎性因子IL-1β、IL-6和TNF-α的分泌,减轻肺上皮细胞炎性损伤,对急性肺损伤具有很好的治疗效果。本发明具有抑制内毒素介导的肺组织免疫炎性反应,抑制免疫炎性损伤介导的纤维化损伤作用,可有效改善肺组织免疫病理损伤过程,对内毒素所致呼吸系统疾病有着良好治疗效果,是一种多功能、多靶点、毒副作用少的中药组合物。
本发明的中药组合物配伍科学合理,治疗效果优异,提高了患者的生活质量,也为治疗急性肺损伤提供了一条新的途径。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明各组大鼠肺组织病理学HE染色结果。
具体实施方式
现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见得的。本发明说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。
实施例1
一种防治内毒素介导的急性肺损伤的中药组合物,原料包括如下重量份数的组分:麦冬4份、双皮3份、沙参3份、炒杏仁4份、百部3份、前胡5份、紫苑4份、半夏4份、青皮5份、桔梗4份、茯苓3份、川贝母3份、瓜蔓4份、厚朴5份、黄芩3份、知母4份、桔红5份。
制备方法如下:
S1.称取规定量的麦冬、双皮、沙参、炒杏仁、百部、前胡、紫苑、半夏、青皮、桔梗、茯苓、川贝母、瓜蔓、厚朴、黄芩、知母、桔红,加水温为35℃~55℃的水过药面2-3cm,浸泡40-60min;
S2.将浸泡后的药材进行煎煮,煮沸后文火煎煮20-30min,收集第一煎药液;
S3.再向中药中加入与第一煎相同的水量,采用与第一煎相同的条件进行第二次煎煮,收集第二煎药液;
S4.合并第一煎药液和第二煎药液,得到中药组合物汤剂。
实施例2
一种防治内毒素介导的急性肺损伤的中药组合物,原料包括如下重量份数的组分:麦冬8份、双皮5份、沙参5份、炒杏仁6份、百部5份、前胡10份、紫苑8份、半夏8份、青皮10份、桔梗8份、茯苓6份、川贝母6份、瓜蔓8份、厚朴10份、黄芩6份、知母8份、桔红10份。
制备方法与实施例1相同。
实施例3
一种防治内毒素介导的急性肺损伤的中药组合物,原料包括如下重量份数的组分:麦冬10份、双皮8份、沙参8份、炒杏仁10份、百部8份、前胡12份、紫苑10份、半夏10份、青皮12份、桔梗10份、茯苓8份、川贝母8份、瓜蔓10份、厚朴12份、黄芩8份、知母10份、桔红12份。
制备方法与实施例1相同。
对比例
一种防治内毒素介导的急性肺损伤的中药组合物,原料包括如下重量份数的组分:麦冬10份、双皮8份、沙参8份、炒杏仁10份、前胡12份、紫苑10份、半夏10份、青皮12份、桔梗10份、茯苓8份、瓜蔓10份、黄芩8份、知母10份、桔红12份。
制备方法与实施例1相同。但组分中缺少百部、川贝母和厚朴,试验结果显示,对内毒素诱导的急性肺损伤无显著改善作用,和模型组相比较结果无显著性差异。
实验例
1.材料
1.1药品
麦冬、双皮、沙参、炒杏仁、百部、前胡、紫苑、半夏、青皮、桔梗、茯苓、川贝母、瓜蔓、厚朴、黄芩、知母、桔红,统一购自北京康仁堂药业有限公司。
1.2动物
SPF级雄性Wistar大鼠72只,体重180-200g,北京维通利华实验动物技术有限公司提供。
2.实验方法
取Wistar大鼠72只,随机分为对照组12只,模型组12只、给药组1-4每组12只,对照组为普通大鼠,模型组和给药组均为经过内毒素刺激后的大鼠,内毒素按照8ng/g剂量肺内灌注;对照组和模型组大鼠按8mL/kg给予生理盐水灌胃,每日1次,共21天;给药组1-3大鼠的配方按8mL/kg给予实施例1-3配置好浓度的中药汤剂灌胃,给药组4大鼠的配方按8mL/kg给予对照例配置好浓度的中药灌胃,每日1次,共21天,实验结果重复3次。第21天处死动物,取血清,检测相关指标,具体方法根据试剂盒说明书执行,试剂盒IL-1β、IL-6、TNF-α、MCP-1、GSH-Px和iNOS均购买于南京建成生物工程研究所。结果见表1。
表1各组大鼠血清中炎性因子和氧化因子水平
注:*与对照组比较p<0.05,△与模型组比较p<0.05。
分别取对照组、模型组和给药组1-4大鼠肺组织,做HE染色切片观察组织形态学变化,见图1。
3.结果与分析
内毒素诱导的急性肺损实验动物模型研究结果显示,炎性因子IL-1β、TNF-α和IL-6表达水平随内毒素的刺激时间的延长,表达水平逐渐升高。指出内毒素介导的急性肺损伤机制与氧化损伤和炎性损伤密切相关。因此,上述指标可作为内毒素诱导急性肺损伤的炎症和氧化损伤的指标。
由上表可见,模型组、给药组1-4与对照组比较,大鼠血清中IL-6、IL-1β、MCP-1、TNF-α表达量显著增高(p<0.05);模型组与给药组1-3具有统计学差异且模型组较给药组表达显著升高(p<0.05),模型组与给药组4有差异,但差异不显著。另外,模型组、给药组1-4血清中GSH-Px和iNOS和对照组大鼠比较表达水平显著下降(p<0.05),且模型组大鼠较给药组1-3大鼠表达更少(p<0.05),较给药组4相比较,差异不显著,说明本发明的中药组合物对于降低炎症因子对组织的损害、抑制炎症反应有较好的效果;而且能够通过增强催化GSH对过氧化物的还原反应的能力,促进机体清除氧自由基,从而抑制脂质过氧化链锁反应,保护细胞膜结构及细胞功能。如图1所示,给药组1-3与模型组相比较,可显著减缓大鼠肺组织损伤;给药组4有一定的作用,但与模型组比较差异不显著。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (9)
1.一种防治内毒素介导的急性肺损伤的中药组合物,其特征在于,包括以下重量份的组分:麦冬4-15份、双皮3-15份、沙参3-15份、炒杏仁4-15份、百部3-15份、前胡5-15份、紫苑4-15份、半夏4-12份、青皮5-15份、桔梗4-15份、茯苓3-12份、川贝母3-15份、瓜蔓4-15份、厚朴5-15份、黄芩3-12份、知母4-12份、桔红5-15份。
2.根据权利要求1所述的中药组合物,其特征在于,包括以下重量份的组分:麦冬10份、双皮8份、沙参8份、炒杏仁10份、百部8份、前胡12份、紫苑10份、半夏10份、青皮12份、桔梗10份、茯苓8份、川贝母8份、瓜蔓10份、厚朴12份、黄芩8份、知母10份、桔红12份。
3.一种权利要求1或2所述的中药组合物的制备方法,其特征在于,包括以下步骤:
S1.按照配比将原料混合后,加水浸泡;
S2.将浸泡后的原料进行第一次煎煮,收集第一煎药液;
S3.再向原料中加入与第一煎相同的水量,采用与第一煎相同的条件进行第二次煎煮,收集第二煎药液;
S4.合并第一煎药液和第二煎药液即可。
4.根据权利要求3所述的制备方法,其特征在于,步骤S1中所述加水用量为过药面2-3cm,所述浸泡水温为35℃-55℃,所述浸泡时间为40-60min。
5.根据权利要求3所述的制备方法,其特征在于,步骤S2中所述煎煮为煮沸后文火煎煮20-30min。
6.一种防治肺损伤的中药制剂,其特征在于,包括治疗有效量的如权利要求1或2所述的中药组合物。
7.根据权利要求6所述的中药制剂,其特征在于,所述中药制剂为口服制剂。
8.一种权利要求1或2所述的中药组合物在制备防治肺损伤药物中的应用。
9.根据权利要求8所述的应用,其特征在于,所述肺损伤包括内毒素介导的急性肺损伤和/或脂多糖引起的肺损伤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111452072.6A CN113952429B (zh) | 2021-12-01 | 2021-12-01 | 一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111452072.6A CN113952429B (zh) | 2021-12-01 | 2021-12-01 | 一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113952429A true CN113952429A (zh) | 2022-01-21 |
CN113952429B CN113952429B (zh) | 2023-07-14 |
Family
ID=79472720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111452072.6A Active CN113952429B (zh) | 2021-12-01 | 2021-12-01 | 一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113952429B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656579A (zh) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | 一种止咳中药组合物 |
CN104547361A (zh) * | 2015-01-16 | 2015-04-29 | 昆明中药厂有限公司 | 一种药物组合物及其制备方法、制剂与应用 |
CN104586979A (zh) * | 2015-01-17 | 2015-05-06 | 塔里木大学 | 一种具有止咳口服液及其制备方法 |
CN106110132A (zh) * | 2016-08-31 | 2016-11-16 | 天津中新药业研究中心 | 一种具有清肺化痰止嗽作用的组合物及其制备方法 |
-
2021
- 2021-12-01 CN CN202111452072.6A patent/CN113952429B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103656579A (zh) * | 2013-12-11 | 2014-03-26 | 山东中大药业有限公司 | 一种止咳中药组合物 |
CN104547361A (zh) * | 2015-01-16 | 2015-04-29 | 昆明中药厂有限公司 | 一种药物组合物及其制备方法、制剂与应用 |
CN104586979A (zh) * | 2015-01-17 | 2015-05-06 | 塔里木大学 | 一种具有止咳口服液及其制备方法 |
CN106110132A (zh) * | 2016-08-31 | 2016-11-16 | 天津中新药业研究中心 | 一种具有清肺化痰止嗽作用的组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
王开武,等: "清金化痰汤联合西药治疗呼吸机相关性肺炎27例", 《中医研究》 * |
王开武,等: "清金化痰汤联合西药治疗呼吸机相关性肺炎27例", 《中医研究》, vol. 28, no. 03, 31 March 2015 (2015-03-31), pages 28 * |
Also Published As
Publication number | Publication date |
---|---|
CN113952429B (zh) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102114113B (zh) | 一种白头翁汤颗粒剂的制备方法 | |
CN101053619B (zh) | 一种治疗肺纤维化的药物 | |
CN111481638A (zh) | 一种治疗溃疡性结肠炎的中药灌肠制剂及其制备方法 | |
CN113952429A (zh) | 一种防治内毒素介导的急性肺损伤的中药组合物及其制备方法 | |
CN101869618B (zh) | 一种治疗痤疮的中药祛痤合剂 | |
CN104225472B (zh) | 一种治疗口腔粘膜病变的中药制剂及制备方法和用途 | |
CN105311470A (zh) | 含有艾叶的药物组合物用于制备治疗糖尿病肾病药物中的用途 | |
CN1706463A (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物 | |
CN104645247B (zh) | 一种治疗肝豆状核变性的中药制剂及其制备方法 | |
CN1176690C (zh) | 一种治疗慢性肾炎的药物 | |
CN116585397B (zh) | 一种用于治疗湿疹的药物组合物及其制备方法和应用 | |
CN102380017A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN108743866B (zh) | 一种红宝舒心口服液及其在用于制备心血管病药物中应用 | |
CN116115687B (zh) | 一种用于痛风的中药组合物及其制备方法和应用 | |
CN116942778B (zh) | 一种用于防治乳腺结节的中药组合物及其应用 | |
CN112826866B (zh) | 一种用于治疗口腔黏膜炎的加味地榆含漱液及其制备方法 | |
CN102526461A (zh) | 一种中药组合物在制备抗心肌细胞缺氧损伤药物中的应用 | |
CN102068611B (zh) | 一种治疗缠腰蛇的外用膏 | |
Wang et al. | Discussion on the medication rule of Professor Ba Yuanming in the treatment of chronic glonerulonephritis based on data mining technology. | |
CN119185429A (zh) | 一种纳米级生发养发组合物及其制备方法、药物制剂及应用 | |
CN115919969A (zh) | 一种治疗高血压的黄芪党参组合物及其制备方法 | |
CN106376928A (zh) | 一种辅助降血糖的复方铁皮石斛保健品制备方法 | |
CN112843170A (zh) | 一种胰脏散的配方 | |
CN112773869A (zh) | 一种治疗白血病的中药组合物 | |
CN105920288B (zh) | 改善胰岛素抵抗综合征的中药制剂及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |